Name: New in @NEJM: Phase 3 LITESPARK-022 showed belzutifan + pembrolizumab significantly improved disease
Uploaded: 2026-07-02T18:30:01+00:00
Description: New in @NEJM: Phase 3 LITESPARK-022 showed belzutifan + pembrolizumab significantly improved disease-free survival in high-risk kidney cancer after surgery. The FDA recently approved the combo in this patient population. Study lead @DrChoueiri of @DanaFarber explains:

Dana-Farber News

@DanaFarberNews

Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu

加入 April 2018

611 正在关注 6.2K 粉丝

Dana-Farber News@DanaFarberNews

2026.07.02 18:30

New in @NEJM: Phase 3 LITESPARK-022 showed belzutifan + pembrolizumab significantly improved disease-free survival in high-risk kidney cancer after surgery. The FDA recently approved the combo in this patient population. Study lead @DrChoueiri of @DanaFarber explains:

显示更多